A Closer Look at Regorafenib

Regorafenib (Stivarga, Bayer) is a once-daily, oral multikinase inhibitor. It first received approval in September 2012 for patients with metastatic colorectal cancer (CRC) who were […]

The Role of Regorafenib in Hepatocellular Carcinoma

H&O What is the mechanism of action of regorafenib? CF The mechanism of action of regorafenib (Stivarga, Bayer) is very similar to that of sorafenib […]